The Truth About XARELTO
Xarelto is a blood thinning medication manufactured by Bayer and marketed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson. Xarelto was designed to prevent strokes and blood clots and was approved by the FDA in 2011. It is specifically marketed to patients diagnosed with A Fib (Atrial Fibrillation) and VTE (Venous Thromboembolism) claiming to be better than the alternative medications. Of all the blood thinners on the market, Xarelto is the second most prescribed. Unfortunately, Xarelto has been linked to serious bleeding events and, unlike its competitors, there is no reversal agent.
Bleeding is common with all blood thinners. However, Xarelto is more dangerous than other blood thinners because no antidote, or reversal agent, exists to reverse its blood-thinning effects. Indeed, a dose of Vitamin K will reverse the effects of Warfarin. Patients taking blood thinners run the risk of irreversible bleeding, including internal and gastrointestinal hemorrhaging, pulmonary embolism, and stroke.
In 2011, a study conducted by ROCKET AF showed that Xarelto was not more effective than Warfarin in preventing bleeding events as its marketing claimed. Also in 2011, the MAGELLAN study compared Xarelto and Lovenox which showed patients taking Xarelto were more than twice as likely to experience bleeding compared to patients on Lovenox. Despite all of this information, neither the manufacturer nor the FDA has recalled Xarelto.
To read the complete FDA label for Xarelto (as of 2015) click here.
In 2014, a multidistrict litigation or Mass Tort was initiated to handle the number of individual lawsuits brought against manufacturer Bayer and Johnson & Johnson for patients who suffered a bleeding event within 24 hours after taking Xarelto. Walsh Woodard LLC is reviewing potential claims from patients who suffered bleeding events associated with Xarelto.